Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-05-29, Stock:NVS, The news for the past five days is as follows:
2019-05-21: NEWS1: Cramer Remix: The cannabis stocks I&apos;m eyeing.NEWS2: Cramer Remix: The cannabis stocks I'm eyeing.NEWS3: Fix 'distortions' in health care system ahead of slate of drug launches: Novartis CEO.NEWS4: Fix 'distortions' in health care system ahead of slate of drug launches: Novartis CEO.NEWS5: Novartis CEO calls for fixing 'distortions' in health care system ahead of slate of drug launches.NEWS6: Novartis CEO calls for fixing &apos;distortions&apos; in health care system ahead of slate of drug launches.NEWS7: Here's Why Array BioPharma Is Surging Today.NEWS8: Here's Why Array BioPharma Is Surging Today.NEWS9: These 3 Major Drug Manufacturers Are Strong Performers.NEWS10: Novartis CEO says cannabis isn&apos;t a focus despite Tilray partnership.NEWS11: Novartis CEO says cannabis isn't a focus despite Tilray partnership.NEWS12: Novartis CEO on single-payer health care: It is not the right move for America.NEWS13: Validea Peter Lynch Strategy Daily Upgrade Report - 5/21/2019.NEWS14: Validea Peter Lynch Strategy Daily Upgrade Report - 5/21/2019.
2019-05-22: NEWS1: Novartis CEO plans gene therapy price 'far lower' than $4 million to $5 million range.NEWS2: Novartis CEO plans gene therapy price 'far lower' than $4 mln to $5 mln range.NEWS3: Novartis Is a Difficult Stock to Trade or Own - Suggested Risk Point.NEWS4: The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study.NEWS5: 3 Bearish Takeaways From the Tilray Earnings Report.NEWS6: 3 Bearish Takeaways From the Tilray Earnings Report.
2019-05-23: NEWS1: Novartis Reports Data on Asthma Drug, Update from Annual Meet.NEWS2: Novartis Reports Data on Asthma Drug, Update from Annual Meet.NEWS3: Novartis Reports Data on Asthma Drug, Update from Annual Meet.NEWS4: Tilray Stock Still Hasn’t Bottomed.NEWS5: Alphabet to Aid Pharma Giants Enhance Clinical Trial Process.NEWS6: Alphabet to Aid Pharma Giants Enhance Clinical Trial Process.NEWS7: Novartis CEO says data quality, lagging innovation crimp China M&A.NEWS8: (Re)Focusing Big Pharma: Novartis CEO Vasant Narasimhan with Jim Cramer at Healthy Returns.NEWS9: After IFM buy, Novartis looks to more early stage biotech M&A.NEWS10: Novartis CEO sees China M&A hampered by data, regulatory standards.NEWS11: Alphabet to Aid Pharma Giants Enhance Clinical Trial Process.NEWS12: Novartis CEO sees chance to accelerate profit margin target.NEWS13: Novartis has 25 blockbusters in the pipeline: CEO.NEWS14: Novartis has 25 blockbusters in the pipeline: CEO.
2019-05-24: NEWS1: Approval of a Game-Changing Gene Therapy for SMA Delivers a Win for Novartis and Regenxbio.NEWS2: For Anderson family, an early bet on SMA gene therapy.NEWS3: Novartis $2 million gene therapy for rare disorder is world's most expensive drug.NEWS4: Novartis $2 mln gene therapy for rare disorder is world's most expensive drug.NEWS5: At $2M, priciest ever medicine treats fatal genetic disease.NEWS6: At $2M, priciest ever medicine treats fatal genetic disease.NEWS7: For Anderson family, an early bet on SMA gene therapy.NEWS8: Novartis gets FDA nod for advanced breast-cancer treatment.NEWS9: Novartis' breast cancer treatment wins FDA approval.NEWS10: FDA approves $2M medicine, most expensive ever.NEWS11: 4 Top Stock Trades for Tuesday: ROKU, ADSK, SPLK, NVS.NEWS12: Novartis' breast cancer treatment wins FDA approval.NEWS13: No Miracle Drug Should Cost $2.1 Million.NEWS14: FDA approves Novartis gene therapy for rare genetic disorder.NEWS15: Novartis Gene Therapy To Cost $2.13 Million, Rivaling Biogen, Ionis.NEWS16: The Funded: One Bay Area biotech goes public while another files IPO plans.NEWS17: FDA okays $2M medicine, most expensive ever.NEWS18: Biogen loses edge on blockbuster rare disease market with Novartis' FDA approval.NEWS19: AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA).NEWS20: FDA approves Novartis' $2.1 million gene therapy — making it the world's most expensive drug.NEWS21: FDA approves Novartis' $2 million gene therapy for spinal muscular atrophy.NEWS22: Novartis Gains FDA Approval For Gene Therapy Rivaling Biogen, Ionis.NEWS23: U.S. approves Novartis gene therapy for rare, deadly muscle disorder.NEWS24: Highlights from CNBC&apos;s Healthy Returns conference.NEWS25: Highlights from CNBC's Healthy Returns conference.NEWS26: Pharma Stock Roundup: MRK's Cancer Biotech Buyout, ABBV, LLY's Pipeline Updates.NEWS27: Novartis wins approval for world’s most expensive drug.
2019-05-28: NEWS1: Conatus Down More Than 60% in the Past 90 Days: Here's Why.NEWS2: Conatus Down More Than 60% in the Past 90 Days: Here's Why.NEWS3: FDA approves most expensive gene therapy ever — and here is its connection to Penn.NEWS4: Conatus Down More Than 60% in the Past 90 Days: Here's Why.NEWS5: Market Morning: Huawei Fumes, Volkswagen Feuds, Novartis Wins, Farage Threatens.NEWS6: A Closer Look at Vanguard Global ESG Select Stock.

Answer: Decrease